# Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome

> **NCT06256432** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Noorik Biopharmaceuticals AG** · enrollment: 54 (estimated)

## Conditions studied

- Hepatorenal Syndrome
- Liver Cirrhosis
- Acute Kidney Injury
- Ascites Hepatic

## Interventions

- **DRUG:** Ambrisentan
- **DRUG:** Terlipressin

## Key facts

- **NCT ID:** NCT06256432
- **Lead sponsor:** Noorik Biopharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-17
- **Primary completion:** 2026-05
- **Final completion:** 2026-06
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06256432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06256432, "Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06256432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*